BioRestorative Therapies (BRTX) vs. Caladrius Biosciences (CLBS) Financial Survey

BioRestorative Therapies (OTCMKTS:BRTX) and Caladrius Biosciences (NASDAQ:CLBS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Insider & Institutional Ownership

7.6% of Caladrius Biosciences shares are held by institutional investors. 43.2% of BioRestorative Therapies shares are held by insiders. Comparatively, 7.5% of Caladrius Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares BioRestorative Therapies and Caladrius Biosciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioRestorative Therapies $80,000.00 101.35 -$9.44 million N/A N/A
Caladrius Biosciences $35.28 million 1.22 $22.97 million ($1.78) -2.45

Caladrius Biosciences has higher revenue and earnings than BioRestorative Therapies.

Profitability

This table compares BioRestorative Therapies and Caladrius Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioRestorative Therapies -9,475.44% N/A -797.20%
Caladrius Biosciences N/A -36.56% -29.87%

Analyst Recommendations

This is a summary of current ratings and recommmendations for BioRestorative Therapies and Caladrius Biosciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioRestorative Therapies 0 0 0 0 N/A
Caladrius Biosciences 0 0 2 0 3.00

Caladrius Biosciences has a consensus target price of $12.75, suggesting a potential upside of 192.43%. Given Caladrius Biosciences’ higher possible upside, analysts clearly believe Caladrius Biosciences is more favorable than BioRestorative Therapies.

Volatility and Risk

BioRestorative Therapies has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Caladrius Biosciences has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.

Summary

Caladrius Biosciences beats BioRestorative Therapies on 7 of the 11 factors compared between the two stocks.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. It also develops the ThermoStem program, a pre-clinical program for the treatment of metabolic diseases, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. In addition, the company provides curved needle device, a needle system with a curved inner cannula that allows access to difficult-to-locate regions for the delivery or removal of fluids and other substances. Further, it offers skin care products under the Stem Pearls brand name. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is headquartered in Melville, New York.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. Its business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. The company was founded in September 1980 and is headquartered in New York, NY.

Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply